Nuzenio

Lyel

Lyel news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 14 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.stsimplywall.st · Sat, 08 Aug 2026 13:28:42 GMT LYEL Oct 2026 31.000 call (LYEL261016C00031000) stock historical prices and data - Yahoo Finance AustraliaYahoo Finance Australia · Fri, 07 Aug 2026 00:40:31 GMT Lyell Immunopharma: Q2 Earnings Snapshot - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 21:39:37 GMT Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMT LYEL: Net loss rose to $44.8M as R&D spending increased; pivotal CAR T-cell trial data expected in 2026–2027 - TradingViewTradingView · Thu, 06 Aug 2026 20:31:05 GMT LYEL: Advanced pivotal trials and strong cash reserves position the company for key milestones ahead - TradingViewTradingView · Thu, 06 Aug 2026 20:28:56 GMT LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - BitgetBitget · Thu, 06 Aug 2026 17:16:33 GMT This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - BenzingaBenzinga · Thu, 06 Aug 2026 14:12:18 GMT

Timeline

Sat, 08 Aug 2026 13:28:42 GMTPossible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.st

Fri, 07 Aug 2026 00:40:31 GMTLYEL Oct 2026 31.000 call (LYEL261016C00031000) stock historical prices and data - Yahoo Finance Australia

Thu, 06 Aug 2026 21:39:37 GMTLyell Immunopharma: Q2 Earnings Snapshot - Yahoo Finance

Thu, 06 Aug 2026 20:35:29 GMTLyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView

Thu, 06 Aug 2026 20:31:05 GMTLYEL: Net loss rose to $44.8M as R&D spending increased; pivotal CAR T-cell trial data expected in 2026–2027 - TradingView

Thu, 06 Aug 2026 20:28:56 GMTLYEL: Advanced pivotal trials and strong cash reserves position the company for key milestones ahead - TradingView

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Lyell Immunopharma8 live mentions Inc5 live mentions Yahoo Finance Australia3 live mentions Immunopharma3 live mentions TradingView TradingView3 live mentions TradingView LYEL3 live mentions Possible Signal As2 live mentions Lyell Immunopharma Insiders2 live mentions Sell US2 live mentions In Stock2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Lyel.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.